Cardiff Oncology announced that the FDA has granted Orphan Drug Designation to onvansertib for treating chronic myelomonocytic leukemia (CMML), a rare and aggressive blood cancer with limited treatment options. This designation supports the development of onvansertib, a PLK1 inhibitor showing promising early clinical results in CMML patients, including improved blood counts and disease stabilization. The status provides benefits like tax credits and market exclusivity, aiding further clinical trials. Cardiff continues to explore onvansertib in other cancers, aiming to address unmet medical needs.
Cardiff Oncology's FDA Orphan Drug Designation for onvansertib is the subject here. For readers following the health sector, of 150 priced US stocks tradable on Pluang, 73 rose and 75 fell today. Notable movers include LQDA at USD 38.98 with a 7.24% increase, DXCM at USD 79.99 down 6.71%, and TNGX at USD 26.93 up 6.67%. These figures are as of Oct 22, 2026 03:02 WIB.
National Healthcare Properties (NHP) announced that Lindsay Gordon, its Executive Vice President and Head of Senior Housing, has been elected to the executive board of the American Senior Housing Association (ASHA). ASHA is a leading national organiz...
Akzo Nobel reported Q3 2026 earnings with revenue of $2.85 billion and EPS of $0.38, both below analyst estimates of $2.96 billion and $0.42 respectively. Despite these misses, the company's core profit exceeded expectations, indicating underlying st...
United Airlines reported a strong third-quarter revenue of $17.9 billion, up 17.4% year-over-year, and provided optimistic guidance for the fourth quarter. Jefferies raised its price target for United Airlines stock to $142 from $134, suggesting a 36...
OFG Bancorp reported third-quarter earnings per share of $1.33, surpassing analyst estimates of around $1.23. However, its revenue came in slightly below expectations at $185.7 million versus estimates near $187 million. The earnings beat was driven ...
SEI Investments is set to report its Q3 2026 earnings on October 21 after market close, with analysts projecting earnings per share of $1.59 and revenue of $658.54 million. These estimates indicate a strong year-over-year growth of 22.3% in earnings ...
